Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD
Even with the second half of the trial yet to be completed, results of the CATALYST trial have initiated a potentially seismic shift in discussions around the management of type 2 diabetes.With the first part of the trial suggesting approximately 1-in-4 patients with difficult-to-control type 2 diabetes, results suggest hypercortisolism could be an underlying driver of suboptimal disease management for millions of people with type 2 diabetes in the US. Now, with this knowledge in hand, the community waits with bated breath for Corcept Therapeutics’ announcement of results from the second half…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.